The Board of Directors at their Meeting held on 12/August/2026 approved the divestment of 2,09,100 equity shares (51.00% of paid up share capital) of Ishwari Healthcare Private Limited. ....

$DIRSHIII PHIRIII IIIDUITRIEE Head Otfice : 30'1, Aura Biplex, Premium Retail Premises, 7, S.V. Fload, Borivali (West), [/umbai - 400092. E-mail : compliance@sudarshanpharma.com Website: www.sudarshanpharma.com Board Line: +91-22-42221111 /43331111 142221116 (100line)rQ1N : L5'1496[4H2008PlC184997 sP r L/cs/sE/2026-2027 / 44 Date: 13th August 2026 The Listing Department BSE Limited BSE Scrip Code: 543828 Phiroze Jeejeebhoy Towers, BSE Trading Symbol: SUDARSHAN Dalal Street, Mumbai- 400 001 lSlN: lNE00TV01023 Sub: lntimation for approval to acquire shares of Sudarshan Maven Pharma Private Limited Ref: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 201-5 Dear Sir / Madam, Pursuant to Regulation 30 of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), this is to inform you that the Board of Directors of the Company have at their meeting held on 12th August 2026, inler-alia, approved divestment of 209,100 equity shares of Rs.10/- each of lshwari Healthcare Private Limited ('lshwari Healthcare') (ClN: U851001V1H2011PTC212867), subsidiary of the Company, equivalent to 51.00% of the paid-up equity share capital of lshwari Healthcare. Upon completion of the divestment, lshwari Healthcare would cease to be subsidiary of the Company. The details as required under the SEBI Listing Regulations read with SEBI Circular SEBI/HO/CFD/PoD2/ClR /Pl0t55 dated Ll.th November 2024 are given in Annexure-A. You are requested to take the same on record. Thanl<s & Regards, Yours faithfully, For, Sudarshan Pharma lndustries ited Hemal Me ffi Chairman & Managing Di Regd. Otf. : 30'1, Aura Biplex, Above Kalyan Jewellers, $.V, Road, Borivali (West), Mumbai - 400092, PHIR]'il XUDIRSHIII IIIDUIIRIEI Head Office : 30'1, Aura Biplex, Premium Retail Premises, 7, S.V. Hoad, Borivali (West), lVlumbai - 400092 E-mail : compliance@sudarshanpharma.com Website : www.sudarshanpharma.com Board Line: +91-22-42221111 /43331111 142221116 (100line)rQ13r1 :151496MH2008P1C184997 Annexure-A Details required under Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations,2075 read with SEBI Circular SEBI/HO/CFD{PID2/C|R/P/0155 dated 11th November 2024 are given below: SL Details to be Provided tnformation L The amount and percentage of the Name: lshwari Healthcare Private Limited turnover or revenue or income and net worth contributed by such unit As on 31't March 2026 or or division undertaking or Authorised Share Capital: Rs.50 Lakhs subsidiary or associate company of Paid Up Share Capital: Rs.4L Lakhs the listed entity during the last Total lncome: Rs.746.21 Lakhs financialyear 2 Date on which the agreement for The Company has not executed any agreement for divestment sale has been entered into; of the equity shares of lshwari Healthcare held by the Company. 3 the expected date of completion of 31't December 2026 sale / disposal 4 consideration received from such Divestment amount shall be decided upon completion of sale / disposal; valuation of lshwari Healthcare. 5 brief details of buyers and whether The Board of Directors has approved the divestment of the any of the buyers belong to the equity shares of lshwari Healthcare held by the Company and promoter / promoter group / group delegated powers to the management to find a buyer for companies. lf yes, details thereof; divestment at the most competitive price. 6 whether the transaction would fall Not Applicable as the buyer is yet to be identified within related party transactions? lf yes, whether the same is done at "arm's length" 7 whether the sale, lease or disposal Not Applicable of the undertaking is outside Scheme of Arrangement? lf yes, Provisions of Regulation 374 are not applicable as the details of the same including subsidiary does not fall under the definition of "Undertaking" as compliance with regulation 37A of defined under clause (a) of sub-section (1) of section 180 of the LODR Regulations. Companies Act, 2013 .:i'1p tI:* Regd. Off. : 301, Aura Biplex, Above Kalyan Jewellers, $,V. Road, Borivali (West), Mumbai - 400092. $DNRSHIII PH[R]{A IIIDUIIRIEX LID Head Otfice : 301, Aura Biplex, Premium Hetail Premi$e$, 7, S.V. Road, Borivali (West), Mumbai - 400092 E"mail : compliance@sudarshanpharma.com WeLsite: www.sudarshanpharma.com Board Line : +91-22-42221111 143331 111 I 422211'16 {100 line) r Qlp : 151496tt/H2008P1C184997 8 additionally, in case of a slump sale, Not Applicable indicative disclosures provided for amalgamation/merger, shall disclosed by the listed entity with ect to such slum sa le For, Sudarshan pharma Industries Limited q\16rnlg Hemal M Chairman & Manag Regd. Otl. : 301, Aura Biplex, Above Kaly*n Jewellers, $.V. Road, Borivali (West), [dumbal - 400092.